Knight Therapeutics Inc. GUD.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 34.27% | 76.32% | 37.98% | 30.46% | 11.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.27% | 76.32% | 37.98% | 30.46% | 11.10% |
| Cost of Revenue | 19.26% | 55.98% | 21.50% | 37.79% | 28.20% |
| Gross Profit | 55.22% | 107.37% | 61.05% | 22.77% | -6.34% |
| SG&A Expenses | 30.47% | 37.86% | 40.62% | 20.56% | 9.45% |
| Depreciation & Amortization | 25.37% | 62.03% | 30.69% | 36.83% | -9.09% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.64% | 54.07% | 27.64% | 34.43% | 16.85% |
| Operating Income | 3,682.40% | 299.87% | 310.66% | -80.03% | -105.50% |
| Income Before Tax | 86.53% | 3,818.85% | 43.11% | -412.20% | -2,265.11% |
| Income Tax Expenses | 142.09% | 141.02% | 183.21% | 254.78% | -211.30% |
| Earnings from Continuing Operations | 73.38% | 530.54% | -17.18% | -4,517.98% | -542.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.38% | 530.54% | -17.18% | -4,517.98% | -542.81% |
| EBIT | 3,682.40% | 299.87% | 310.66% | -80.03% | -105.50% |
| EBITDA | 101.53% | 363.16% | 155.96% | 9.90% | -33.44% |
| EPS Basic | 73.03% | 537.25% | -16.25% | -4,700.00% | -554.29% |
| Normalized Basic EPS | 199.40% | 71,800.00% | 189.87% | -0.97% | -940.63% |
| EPS Diluted | 73.72% | 582.01% | -10.88% | -4,933.33% | -543.84% |
| Normalized Diluted EPS | 199.40% | 71,500.00% | 189.87% | -0.97% | -940.63% |
| Average Basic Shares Outstanding | -1.44% | -1.19% | -1.19% | -1.46% | -1.68% |
| Average Diluted Shares Outstanding | -1.44% | -1.15% | -1.07% | -1.46% | -1.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |